- Jul 25, 2001 BIOCRYST REPORTS SECOND QUARTER 2001 FINANCIAL RESULTS
- Jul 19, 2001 BIOCRYST TO RELEASE SECOND QUARTER FINANCIAL RESULTS ON JULY 25, 2001
- Apr 30, 2001 ORTHO-McNEIL PHARMACEUTICAL, INC. AND THE R. W. JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE TO TERMINATE WORLDWIDE INFLUENZA COLLABORATION
- Apr 25, 2001 BIOCRYST REPORTS FIRST QUARTER 2001 FINANCIAL RESULTS
- Apr 19, 2001 BIOCRYST TO RELEASE FIRST QUARTER FINANCIAL RESULTS ON APRIL 25, 2001
- Feb 1, 2001 BIOCRYST REPORTS 2000 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
- Jan 25, 2001 BIOCRYST TO RELEASE FOURTH QUARTER FINANCIALS ON FEBRUARY 1, 2001
- Dec 22, 2000 THE R.W. JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE UPDATES BIOCRYST
- Oct 25, 2000 BIOCRYST REPORTS THIRD QUARTER 2000 FINANCIAL RESULTS
- Oct 20, 2000 BIOCRYST INVITES YOU TO JOIN ITS THIRD QUARTER 2000 CONFERENCE CALL
- Oct 12, 2000 BIOCRYST PHARMACEUTICALS, INC. PROVIDES UPDATE ON ORAL INFLUENZA NEURAMINIDASE INHIBITOR PROGRAM WITH THE R.W. JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
- Sep 8, 2000 PROMISING NEW FLU DRUG UNDER DEVELOPMENT HAS ANTIVIRAL ACTIVITY AGAINST BOTH TYPES OF INFLUENZA IN HUMAN CHALLENGE MODELS
- Sep 8, 2000 NEW ANTIVIRAL DRUG IS EFFECTIVE AGAINST AVIAN INFLUENZA STRAINS RESPONSIBLE FOR THE 1997 HONG KONG OUTBREAK
- Jul 26, 2000 BIOCRYST REPORTS SECOND QUARTER 2000 FINANCIAL RESULTS
- May 8, 2000 PRESIDENT AND CHIEF OPERATING OFFICER OF BIOCRYST PHARMACEUTICALS IS HONORED BY THE ASSOCIATION OF AMERICAN PHYSICIANS
- Apr 26, 2000 BIOCRYST REPORTS FIRST QUARTER 2000 FINANCIAL RESULTS
- Feb 8, 2000 BIOCRYST TO RECEIVE $4 MILLION MILESTONE PAYMENT IN CONNECTION WITH INITIATION OF PHASE III STUDIES OF ORAL NEURAMINIDASE INHIBITOR RWJ-270201 (BCX-1812) IN NORTH AMERICA AND EUROPE
- Feb 2, 2000 BIOCRYST REPORTS 1999 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
- Jan 10, 2000 BIOCRYST APPOINTS W. RANDALL PITTMAN CHIEF FINANCIAL OFFICER
- Jan 7, 2000 BIOCRYST PHARMACEUTICALS PROVIDES UPDATE ON ORAL INFLUENZA NEURAMINIDASE INHIBITOR PROGRAM WITH R.W. JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
BCRX - NASDAQ